Advertisement

Effects of Antihypertensive Treatment on Peripheral Flow of the Lower Limbs

  • A. Pinto
  • F. Riolo
  • A. M. Notarbartolo
  • G. Avellone
  • D. Galati
  • F. Clemenza
  • D. Gullotti
  • A. Strano
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)

Abstract

The clinical pattern determined in subjects that undergo a high and prolonged pressure regime is defined as “hypertensive disease”.

Keywords

Arterial Hypertension Essential Hypertension Antihypertensive Treatment Resistant Hypertension Intermittent Claudication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. B. Atkinson, J. Brown, A. F. Lever, J. I. S. Robertson, Combined treatment of severe intractable hypertension with Captopril and diuretic. Lancet 8186:105 (1980).CrossRefGoogle Scholar
  2. 2.
    A. B. Atkinson, J. J. Morton, J. Brown, D. L. Davies, R. Fraser, P. Kelly, B. Leckie, A. F. Lever, J. I. S. Robertson, Captopril in clinical hypertension. Changes in componentes of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme. Br.Heart J. 44:290 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    S. A. Atlas, D. B. Case, J. E. Sealey, J. H. Laragh, D. N. McKinstry, Interruption of the renin-angiotensin system in hypertensive patients by Captopril induces sustained production in aldosterone secretion, potassium retention and natriuresis. Hypertension 1:274 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    C. L. Berry, Hypertension and arterial development. Long-term consideration. Br. Heart J. 40:709 (1978)PubMedCrossRefGoogle Scholar
  5. 5.
    C. A. Bloxham, D. G. Beevers, J. M. Walker, Malignant hypertension and cigarette smoking. Br.Med.J. 1:581 (1979.PubMedCrossRefGoogle Scholar
  6. 6.
    C. Brater, S. Anderson, C. Muckleroy, Effects in normal subjects of long term administration of azosenide. Clin. Pharmacol. Ther. 26:437 (1979).PubMedGoogle Scholar
  7. 7.
    H. R. Brunner, H. Gavras, B. Waeber, S. C. Textor, G. A. Turini, J. P. Wanters, Clinical use of an orally acting converting enzyme inhibitor: Captopril. Hypertension 2:558 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    C. J. Bulpitt, L. J. Beilin, P. Clifton, C. T. Dollery, G. S. Harper, E. C. Coles, J. S. S. Gear, B. F. Johnson, A. D. Munro-Faure, Risk factors for death in treated hypertensive patients. Report from the D.H.S.S. hypertension care computing project. Lancet 8134:134 (1979).CrossRefGoogle Scholar
  9. 9.
    C. Cavallaro, Modificazioni della parete arteriosa nell’aterosclerosi. In: “Cardiologia d’Oggi”, Vol. 1 p. 193, Mediche Scientifiche, ed., Torino, 1975).Google Scholar
  10. 10.
    A. W. Jr. Cowley, The concept of autoregulation of total blood flow and its role in hypertension. Am.J.Med. 68:906 (1980).CrossRefGoogle Scholar
  11. 11.
    D. S. Davies, J. L. Reid, Central cardiovascular actions of clonidine. In: “Central Action of Drugs in Blood Pressure Regulation”, The Whitefriers Press, ed., London, (1975).Google Scholar
  12. 12.
    C. De Mey, D. Wellens, P. M. Vanhoutte, Fisiopathology and pharmacotherapy of occlusive arterial disorders. Angiology 30:433 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Ebringer, A. E. Doyle, T. R. Dawborn, Clonidine in the treatment of hypertension. Br. Med. J. 1:402 (1971).PubMedCrossRefGoogle Scholar
  14. 14.
    B. Fagrell, Digital pulse plethysmography and digital blood pressure measurement in the evaluation of arterial circulation in the lower limbs. Scand. J. Clin. Lab. Invest. 31:128 (1973).CrossRefGoogle Scholar
  15. 15.
    K. Roger, R. K. Ferguson, H. Peter, J. Vlasses, D. Pharm, R. Janice, R. N. Kojlin, B. S. Anne Shirinian, F. James, J. Burke, C. John, R. Alexander, Captopril in severe treatment-resistant hypertension. Am. Heart J. 99:579 (1980).CrossRefGoogle Scholar
  16. 16.
    S. Forconi, A. Jagenau, M. Guerrini, S. Pecchi, R. Cappelli, Strain-gauge plethysmography in the study of circulation of the limbs. Angiology 30:487 (1979).PubMedCrossRefGoogle Scholar
  17. 17.
    W. I. Frishman, S. Halprin, Clinical pharmacology of the new beta-adrenergic blocking drugs. VII. New Horizons in beta-adrenoceptor blockade therapy: Labetalol. Am. Heart J. 98:660 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    H. Gravas, Antihypertensive effects of the oral angiotensin converting-enzyme inhibitor. New Engl. J. Med. 298:991 (1978).CrossRefGoogle Scholar
  19. 19.
    R. M. Greenhangh, D. S. Rosengarten, I. Mervert, B. Lewis, J. S. Colman, P. Martin, Serum lipids and lipoproteins in peripheral vascular desease. Lancet 2:947 (1971).CrossRefGoogle Scholar
  20. 20.
    B. Gribbin, T. G. Pickerilg, P. Sleight, Arterial distensibility in normal and ipertensive man. Clin. Sci. 56:413 (1979).PubMedGoogle Scholar
  21. 21.
    L. Hansson, S. N. Hunyor, S. Julius, S. W. Hobler, Blood pressure crisis following withdrawal of Clonidine. Am. Heart J. 85:605 (1973).PubMedCrossRefGoogle Scholar
  22. 22.
    S. W. Hoobler and E. Sagastume, Clonidine hydrochloride in the treatment of hypertension. Am. J. Cardiol. 28:67 (1971).PubMedCrossRefGoogle Scholar
  23. 23.
    W. G. Hughson, J. Mann and A. Garrod, Intermittent claudication: prevalence and risk factors. Br. Med. J. 1:1379 (1978).PubMedCrossRefGoogle Scholar
  24. 24.
    K. Hutchinson and H. Williams, Calf blood flow and ankle systolic blood pressure in intermittent claudication monitored over five years. Angiology 29:719 (1978).CrossRefGoogle Scholar
  25. 25.
    R. G. Hutchinson, Medical management of hypertension. Angiology 30:558 (1979).PubMedCrossRefGoogle Scholar
  26. 26.
    G. Koch, Haemodynamic effects of combined alpha and beta-adrenoceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise. Br. J. Clin. Pharmacol. 3(Suppl.):725 (1976).PubMedGoogle Scholar
  27. 27.
    G. Koch, Effetti emodinamici del blocco alfa e beta-recettoriale acuto con somministrazione di labetalolo e.v. e variazioni in corso di trattamento orale protratto in pazienti affetti da ipertensione essenziale. in: “Atti Convegno Venezia”, p.65 (1978).Google Scholar
  28. 28.
    H. Koffer, P. H. Vlasses, R. K. Ferguson, M. Weiss and A. G. Abler, Captopril in diuretic treated hypertensive patients. J.A.M.A. 244:2532 (1980).PubMedCrossRefGoogle Scholar
  29. 29.
    B. O. Kristensen and J. Skork, Captopril or frusemide in drug-resistant hypertension (Letter) Lancet 8196:699 (1980).Google Scholar
  30. 30.
    D. W. Johns, K. M. Baker, C. R. Ayers, E. D. Vanghau Jr., R. M. Carey, M. J. Peach, M. R. Yancey, E. M. Ortt and S. C. Williams, Acute and chronic effect of Captopril in hypertensive patients. Hypertension 2:567 (1980).PubMedCrossRefGoogle Scholar
  31. 31.
    C. L. Johnson, B. P. McGrath, J. A. Miller and P. G. Mathews, Long term effects of Captopril (SQ 14 225) on blood pressure and hormone levels in essential hypertension. Lancet 8141:493 (1979).CrossRefGoogle Scholar
  32. 32.
    P. Lijnen, R. Fagard, J. Staessen, L. J. Verschueren and A. Amery, Dose response in Captopril therapy of hypertension. Clin. Pharmacol. Ther. 28:310 (1980).PubMedCrossRefGoogle Scholar
  33. 33.
    G. M. London, M. E. Safar, Y. A. Weiss and A. Simon, Total effective Compliance of the vascular bed in essential hypertension. Am. Heart J. 95:325 (1978).PubMedCrossRefGoogle Scholar
  34. 34.
    G. A. McGregor, N. D. Markandu, J. E. Roulston and J. C. Jones, Essential hypertension: effect of an oral inhibitor of angiotensin converting enzyme. Br. Med. J. 2:1106 (1979).CrossRefGoogle Scholar
  35. 35.
    A. Maruyama, T. Ogihara, T. Naka, H. Mikami, T. Hata, M. Nakamaru, K. Iwanaga and Y. Kumahara, Long term effects of Captopril in hypertension. Clin. Pharmacol. Ther. 28:316 (1980).PubMedCrossRefGoogle Scholar
  36. 36.
    G. Mattioli, S. Ricci and P. Bertoncelli, Haemodynamics of hypertension. Changes caused by beta blocking agents. Minerva Cardioangiol. 27:463 (1979).PubMedGoogle Scholar
  37. 37.
    P. Mayer, J. L. Elghozi and J. P. Grünfield, The physiological basis of the treatment of arterial hypertension. Nouv. Presse Med. 8:2325 (1979).Google Scholar
  38. 38.
    F. Messerly, J. De Carvalho, B. Christie and B. Fröhlich, Systemic and regional haemodynamics in low, normal and high cardiac output borderline hypertension. Circulation 58:441 (1978).CrossRefGoogle Scholar
  39. 39.
    J. Metha and J. N. Cohn, Haemodynamic effects of labetalol, an alpha and beta-adrenoceptor blocking agent, in hypertensive subjects. Circulation 55:370 (1977).CrossRefGoogle Scholar
  40. 40.
    C. Alicandri, E. Agabiti-Rosci, R. Fariello, L. Corea and B. Muiesan, Effetti emodinamici della somministrazione acuta e cronica del labetalolo nell’ipertensione arteriosa. in: “Atti Convegno Venezia”, p.31 (1978).Google Scholar
  41. 41.
    K. D. Boch, P. Merguet and V. H. Heimsoth, Effect of Clonidine on regional blood flow and its use in the treatment of hypertension, in: “Hypertension: Mechanisms and Management”, G. Onesti, K.E. Kim and J.A. Mayer eds., Grune and Stratton Inc. p.395 New York, (1973).Google Scholar
  42. 42.
    L. H. Opie, Drugs and the heart. III Calcium antagonist. Lancet 8172:806 (1980).CrossRefGoogle Scholar
  43. 43.
    W. A. Pettinger, Clonidine a new antihypertensive drug. New. Engl. J. Med., 293:1179 (1975).PubMedCrossRefGoogle Scholar
  44. 44.
    G. Thomas, T. G. Pickering, H. John and P. Laragh, Auto-regulation as a factor in peripheral resistance and flow: clinical implications for analysis of high blood pressure (editorial). Am.J.Med. 68:801 (1980).CrossRefGoogle Scholar
  45. 45.
    A. Pinto, La semeiotica strumentale delle arteriopatie obliteranti degli arti inferiori. Coliana di quaderni monografici a cura di E. Massari. in: “Patologia arteriosa distrettuale”, E.S.I. Redaz. Stampa Medica.Google Scholar
  46. 46.
    B. N. C. Pichard, Beta-adrenoceptor blocking agents in the management of hypertensionGoogle Scholar
  47. 47.
    L. E. Ramsay, Intermittent claudication in hypertensive men. Journal of the Royal College of Physicians of London 13:100 (1979).PubMedGoogle Scholar
  48. 48.
    J. L. Reid, H. J. Dargie and C. T. Dollery, Clonidine withdrawal in hypertension. Lancet 2:1171 (1977).CrossRefGoogle Scholar
  49. 49.
    D. A. Richards and E. P. Wooding, The effects of oral AH 5158, a combined alpha and beta-adrenoceptor antagonist in healthy volunteers. Br. J. Clin. Pharmacol. 1:505 (1974).PubMedCrossRefGoogle Scholar
  50. 50.
    A. Simon, B. Levy, Y. Weiss, M. Kheder and J. Levenson, Arterial compliance in permanent essential hypertension. Angiology 29:402 (1978).PubMedCrossRefGoogle Scholar
  51. 51.
    A. Simon, M. A. Safar, J. Levenson, A. Kheder and B. Levy, Systolic hypertension: haemodynamic mechanism and choice of anti-hypertensive treatment. Am. J. Cardiol. 44:505 (1979).PubMedCrossRefGoogle Scholar
  52. 52.
    J. Stamler, Prevenzione primaria e secondaria delle malattie aterosclerotiche. in: “Arteriosclerosi”, Vol.11, R. Paoletti and CR. Sirtori (Coord.), Ambrosiana, Milano, (1977).Google Scholar
  53. 53.
    R. Stamler, J. Stamler, W. F. Riedlinger, G. Algera and R. H. Roberts, Family (parental) history and prevalence of hypertension. Results of a nationwide screening program. J.A.M.A. 241:43 (1979).PubMedCrossRefGoogle Scholar
  54. 54.
    A. Strano, S. Novo, G. Davi, A. Pinto and R. P. Riolo, Aspetti epidemiologici delle arteriopatie degli arti. in: “Giornate Angiologiche Fiorentine”, Firenze 14 Giugno (1979).Google Scholar
  55. 55.
    A. Strano, Fattori emodinamici nell’aterosclerosi. in: “Aterosclerosi: problemi di patologia e terapia”. Incontri con i medici 1977–1979, a cura della Direzione Medica Janssen.Google Scholar
  56. 56.
    A. Takeshita and A. L. Mark, Decreased vasodilator capacity of forearm resistance vessels in borderline hypertension. Hipertension 2:610 (1980).CrossRefGoogle Scholar
  57. 57.
    P. A. Van Zwieten, The central action of antihypertensive drugs, mediated via central alpha-receptors. J. Pharm. Pharmaco1. 25:89 (1973).Google Scholar
  58. 58.
    J. K. Vyden, J. Thorner, K. Nagasewa, T. Takano, M. F. Groseth-Dittrich, R. Perlow and M. J. Swen, Metabolic and cardiovascular abnormalities in patients with peripheral arterial disease. Am. Heart J. 90:703 (1975).PubMedCrossRefGoogle Scholar
  59. 59.
    P. Weidmann, R. De Chatle, W. H. Ziegler, J. Flammer and F. Reubi, Alpha and beta-adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and catecholamine excretion. Am. J. Cardiol. 41:570 (1978).PubMedCrossRefGoogle Scholar
  60. 60.
    M. J. Wendeburg, Prolonged treatment of high renin hypertension with a converting enzyme inhibitor. Br. Med. J. 2:866 (1978).CrossRefGoogle Scholar
  61. 61.
    L. Werko, Vascular adaptation to long term blood pressure reduction (Letter). Acta Med.Scand. 207:207 (1980).PubMedGoogle Scholar
  62. 62.
    A. Zanghetti, Overview of cardiovascular reflexes in hypertension. Am. J. Cardiol. 44:912 (1979).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • A. Pinto
    • 1
  • F. Riolo
    • 1
  • A. M. Notarbartolo
    • 1
  • G. Avellone
    • 1
  • D. Galati
    • 1
  • F. Clemenza
    • 1
  • D. Gullotti
    • 1
  • A. Strano
    • 1
  1. 1.Institute of Clinical Medicine and Medical Therapy I°University of PalermoPalermoItaly

Personalised recommendations